Table 1.
Characteristics of GC cases of survival study in the Shanxi Upper Gastrointestinal Genetics Project
| Overall (n = 1147) | Alive (n = 319) | Deceased (n = 828) | |||||
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | HR (95% CI) | P a | HR (95% CI) | P b | |
| Age, mean (SD) | 58.1 (9.2) | 56.5 (9.37) | 58.7 (9.06) | 1.17 (1.08–1.26) | <0.0001 | 1.15 (1.06–1.24) | 5.0E-4 |
| Sex | |||||||
| Male | 939 (81.9) | 267 (83.7) | 672 (81.2) | 1 (Reference) | 1 (Reference) | ||
| Female | 208 (18.1) | 52 (16.3) | 156 (18.8) | 1.06 (0.89–1.26) | 0.53 | 1.11 (0.93–1.32) | 0.26 |
| Follow-up years, Median | 1.72 | 5.12 | 1.17 | ||||
| Primary tumor location | |||||||
| Non-cardia | 435 (37.9) | 144 (45.1) | 291 (35.1) | 1 (Reference) | 1 (Reference) | ||
| Cardia | 712 (62.1) | 175 (54.9) | 537 (64.9) | 1.30 (1.12–1.52) | 0.001 | 1.20 (1.03–1.40) | 0.02 |
| Lauren classification | |||||||
| Intestinal | 495 (55.3) | 145 (59.4) | 350 (53.8) | 1 (Reference) | 1 (Reference) | ||
| Diffuse | 400 (44.7) | 99 (40.6) | 301 (46.2) | 1.21 (1.03–1.43) | 0.02 | 1.20 (1.02–1.42) | 0.03 |
| Missing | 252 | 75 | 177 | ||||
| Grade | |||||||
| Well or moderately differentiated | 371 (33.0) | 133 (42.8) | 238 (29.2) | 1 (Reference) | 1 (Reference) | ||
| Poorly or undifferentiated | 755 (67.1) | 178 (57.2) | 577 (70.8) | 1.29 (1.10–1.52) | 0.002 | 1.34 (1.14–1.57) | 4.0E-4 |
| Missing | 21 | 8 | 13 | ||||
| T stage | |||||||
| T1–T2 | 83 (7.3) | 52 (16.4) | 31 (3.8) | 1 (Reference) | 1 (Reference) | ||
| T3–T4 | 1056 (92.7) | 265 (83.6) | 791 (96.2) | 1.94 (1.34–2.82) | 0.001 | 2.11 (1.46–3.06) | <0.0001 |
| Missing | 8 | 2 | 6 | ||||
| Regional lymph nodes (N) | |||||||
| N0 | 213 (20.8) | 109 (41.6) | 104 (13.6) | 1 (Reference) | – | ||
| N1 | 247 (24.1) | 71 (27.1) | 176 (23.0) | 0.41 (0.12–1.39) | 0.15 | – | |
| N2 | 319 (31.1) | 61 (23.3) | 258 (33.8) | 0.58 (0.17–1.99) | 0.39 | – | |
| N3 | 247 (24.1) | 21 (8.0) | 226 (29.6) | 0.98 (0.29–3.32) | 0.98 | – | |
| Missing | 121 | 57 | 64 | ||||
| Distant metastasis (M) | |||||||
| M0 | 322 (28.5) | 162 (51.8) | 160 (19.6) | 1 (Reference) | 1 (Reference) | ||
| M1 | 809 (71.5) | 151 (48.2) | 658 (80.4) | 3.89 (1.16–13.0) | 0.03 | 2.39 (2.00–2.86) | <0.0001 |
| Missing | 16 | 6 | 10 | ||||
| Cancer treatment group after surgery | |||||||
| Surgery only | 588 (51.3) | 166 (52.0) | 422 (51.0) | 1 (Reference) | |||
| Chemotherapy | 453 (39.5) | 131 (41.1) | 322 (38.9) | 0.92 (0.68–1.25) | 0.59 | – | |
| Radiotherapy | 17 (1.5) | 2 (0.6) | 15 (1.8) | 0.90 (0.66–1.22) | 0.49 | – | |
| Chemotherapy and radiotherapy | 57 (5.0) | 10 (3.1) | 47 (5.7) | 0.78 (0.47–1.31) | 0.35 | – | |
| Herbs or others | 31 (2.7) | 10 (3.1) | 21 (2.5) | 1.71 (0.95–3.06) | 0.07 | – | |
| Missing | 1 | 1 | |||||
Follow-up years: years from date of surgery to date of death or end-of-follow-up.
aAdjusted for age (10-year frequency), sex, primary tumor location, lauren classification, grade, T stage, regional lymph nodes, and distant metastasis.
bAdjusted for age (10-year frequency), sex, primary tumor location, lauren classification, grade, T stage, and distant metastasis.
SD, standard deviation.